Evotec SE (EVO) Net Income towards Common Stockholders (2020 - 2025)

Evotec SE's (EVO) quarterly Net Income towards Common Stockholders came in at -$100.9 million in Q4 2025, up 51.3% year-on-year from -$66.7 million in Q4 2024, and down 200734.07% quarter-over-quarter from -$50222.6 in Q3 2025.

Evotec SE (EVO) Net Income towards Common Stockholders (2020 - 2025) Analysis & Trends

Evotec SE has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$100.9 million for Q4 2025.

  • Net Income towards Common Stockholders for Q4 2025 came in at -$100.9 million, up 51.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$100.9 million (up 51.28% YoY), and the FY2025 annual result was -$120.5 million, up 42.49% from the prior year.
  • Net Income towards Common Stockholders came in at -$100.9 million for Q4 2025 at Evotec SE, down from -$50222.6 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $246.3 million in Q4 2021 to a low of -$207.1 million in Q4 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$29810.4 (2022), against an average of -$22.1 million.
  • Across the five-year window, Net Income towards Common Stockholders surged 9714.16% in 2021 and plunged 229.31% in 2022, its largest moves.
  • Evotec SE's Net Income towards Common Stockholders stood at $246.3 million in 2021, then slumped by 172.84% to -$179.4 million in 2022, then jumped by 49.69% to -$90.2 million in 2023, then slumped by 129.5% to -$207.1 million in 2024, then surged by 51.3% to -$100.9 million in 2025.
  • The last three Net Income towards Common Stockholders figures came in at -$100.9 million (Q4 2025), -$50222.6 (Q3 2025), and -$207.1 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 366.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 601.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 274.90 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 1.99 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 197.90 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 57.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -66.53 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -92.12 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 118.42 Mn
10 Evotec SE 570.60 Mn 570.08 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -100.86 Mn
Sep 30, 2025 -50,222.61
Dec 31, 2024 -207.09 Mn
Sep 30, 2024 -51,477.94
Dec 31, 2023 -90.24 Mn
Sep 30, 2023 42,406.04
Jun 30, 2023 -22,254.35
Dec 31, 2022 -179.36 Mn
Sep 30, 2022 47,666.17
Jun 30, 2022 -29,810.36
Mar 31, 2022 -82,202.26
Dec 31, 2021 246.25 Mn
Sep 30, 2021 158,344.09
Jun 30, 2021 72,274.35
Mar 31, 2021 63,571.06
Dec 31, 2020 7.48 Mn
Sep 30, 2020 -1,646.99